Vator Securities Sole Bookrunner in Nanoform SEK 71 million private placement, Borenius legal advisor in joint Swedish-Finnish operation
The private placement was directed to Swedish and Finnish, HNWI, family offices and institutional investors where Mandatum Life Insurance Company (Sampo Group) acted as anchor investor.
Every year only 30-60 drugs are approved by regulatory authorities. Failures in trials cost €50bn. Nanoform can give failed drug molecules a second chance by providing ground breaking services in nanotechnology and drug particle engineering for the international pharma industry. Nanoform’s proprietary technology, Controlled Expansion of Supercritical Solutions (CESS) is a tested and proven method whereby nanonization (the process of shrinking drug particles without changing its chemical properties) takes place. The company has already successfully nanonized several active pharmaceutical ingredients (APIs). The process is more controlled than conventional supercritical technologies and can produce smaller and more uniformly sized particles in an industry where particle size is critical. An aging global population increases the demand for new drugs ensuring a rapidly growing addressable market.
Edward Hæggström, CEO of Nanoform: “Vator Securities is a great advisory partner for us. Their relationships and sector knowledge have been invaluable in this investment round. Their network of very experienced senior industrial advisors combined with solid financial market knowledge and entrepreneurial spirit has made them an excellent advisor and sparring partner for Nanoform. I also want to welcome all new investors in Nanoform and thank everyone involved in this investment round for a very smooth process. With the new proceeds we will build GMP level production and commercialize internationally”.
Homan Panahi, CEO Vator Securities: “We are delighted to have successfully advised Nanoform on this transaction. Edward and his highly-experienced team of specialists are at the forefront of Controlled Expansion of Supercritical Solutions (CESS), and we see significant opportunities for Nanoform to transform the way drug development is done.”
Albert Hæggström, CFO of Nanoform:” Special thanks in this process goes to our legal advisor Peter Hänninen at Borenius and senior partner Henri von Haartman at Vator. Their execution and service were impeccable.”
For further information,
Homan Panahi, CEO, Vator Securities
Tel: +46 763-98 96 66
E-post: homan@vatorsec.se
About Vator Securities
Vator Securities provides an extensive range of capital markets and advisory services to cutting-edge public and private growth companies with an emphasis on the Life Sciences, Medical Technology and Diagnostics industries. Vator Securities executes on opportunities that accelerate growth for its client companies while delivering results to the firm’s sophisticated investor clientele. Vator Securities distinguishes itself by the firm’s ability to raise capital from traditional institutional investors, as well as from its proprietary global network of family office and high net worth investors. Vator Securities was founded in Stockholm in 2009 and the firm is primarily an equity partnership.